2008
DOI: 10.1007/s12094-008-0159-z
|View full text |Cite
|
Sign up to set email alerts
|

Epidermal growth factor receptor and glioblastoma multiforme: molecular basis for a new approach

Abstract: High-grade gliomas are the most common primary malignant brain tumours. Surgery, radiotherapy and chemotherapy are the cornerstone of actual treatment. In spite of large therapeutic efforts, overall survival is still poor. New molecular data allow a new molecular classification for high-grade gliomas and open a therapeutic window for targeted therapy. Molecular diagnostic tools may provide a basis for receptor-based therapies and enough information to personalise future treatments. In this regard, epidermal gr… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
15
0
4

Year Published

2008
2008
2015
2015

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 24 publications
(20 citation statements)
references
References 24 publications
1
15
0
4
Order By: Relevance
“…It is possible that a therapeutic window exists, which permits inhibition of Ape-1/Ref-1 redox function in the tumor endothelium while preserving sufficient function required for viability of normal endothelial cells. Certainly, analogous therapeutic windows have been reported in clinical studies targeting other essential cellular pathways, such as Hedgehog and epidermal growth factor receptor pathways (Belda-Iniesta et al, 2008;Garber, 2008). Of note, the susceptibility of tumor endothelial cells to inhibition of the Ape-1/Ref-1 redox domain using E3330 was greater than that of embryonic stem cells undergoing hematopoietic differentiation, as we have previously demonstrated (Zou et al, 2007).…”
Section: Discussionsupporting
confidence: 71%
“…It is possible that a therapeutic window exists, which permits inhibition of Ape-1/Ref-1 redox function in the tumor endothelium while preserving sufficient function required for viability of normal endothelial cells. Certainly, analogous therapeutic windows have been reported in clinical studies targeting other essential cellular pathways, such as Hedgehog and epidermal growth factor receptor pathways (Belda-Iniesta et al, 2008;Garber, 2008). Of note, the susceptibility of tumor endothelial cells to inhibition of the Ape-1/Ref-1 redox domain using E3330 was greater than that of embryonic stem cells undergoing hematopoietic differentiation, as we have previously demonstrated (Zou et al, 2007).…”
Section: Discussionsupporting
confidence: 71%
“…More than 27,000 of these tumors were classified as glioblastoma (GBM), which is the most common and aggressive type of primary brain tumor (Louis, 2007). The conventional care for patients diagnosed with GBM is based on the combination of maximal safe surgical resection with chemotherapy and radiotherapy treatments (Belda-Iniesta, 2008; Clarke, 2010; Stupp, 2009; Stupp, 2005; Stupp, 2010). Despite the use of adjuvant radiation and chemotherapy, tumor recurrence is observed in nearly all instances, and the median survival for GBM patients has seen only modest improvement, to approximately 15 months (CBRTUS, 2010).…”
Section: Introductionmentioning
confidence: 99%
“…To further this end, comprehensive growth factor blocking and a multimodal approach should be explored as per the recent trenchant advocacy by Lefranc [36]. Since many of the growth-enhancing signalling systems operative in glioblastoma intersect with each other and therefore can cross-cover [37,38], they all must be blocked or thwarted for cure. This current short note supports that contention and suggests a small fi rst step to that end by blocking SP signalling by using aprepitant.…”
Section: Resultsmentioning
confidence: 99%